Neutrophil gelatinase-associated lipocalin is released from secondary granules of activated neutrophils. It is an iron scavenger that prevents bacterial growth. This protein is also produced by renal tubular cells, secondary to injury, for instance as a result of ischemia. Thus it is used as an early marker of acute kidney injury. During sepsis, it appears that NGAL is also released by activated leukocytes. Severe sepsis is a major cause of mortality and morbidity in neonates at neonatal intensive care units. As the manifestations of sepsis are nonspecific in neonates and there are delays in taking cultures, there is difficulty with diagnosis of sepsis in neonates especially during early phases. On the other hand early diagnosis and intervention may be helpful in saving lives. On this basis, researchers have tried to find markers with high positive and negative predictive values for identifying neonates at risk of sepsis. One of these markers is serum and/or urinary NGAL. Parravicini et al. measured urinary NGAL in late onset sepsis in very low birth weight (VLBW) infants. They found a sensitivity of 75%, specificity of 84%, positive predictive value of 67% and negative predictive value of 89% (
2,
3). They concluded that urinary NGAL is a suitable marker for early diagnosis of sepsis in VLBW neonates. To our knowledge, this is the first study to assess serum NGAL for the diagnosis of sepsis in neonates. We found that serum NGAL was low in neonates without sepsis and high in neonates with sepsis. This suggests that serum NGAL can be a biomarker of sepsis in neonates. We also found a cut-off value of 48 ng/mL for distinguishing septic from non-septic neonates with a sensitivity of 92% and specificity of 91%.